G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2024

The g-csf (granulocyte colony stimulating factors) market size has grown steadily in recent years. It will grow from $8.84 billion in 2023 to $9.17 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth observed in the historical period can be ascribed to an upsurge in cancer prevalence, robust economic expansion in emerging markets, heightened healthcare expenditure, an increase in pharmaceutical research and development expenditure, and government initiatives.

The g-csf (granulocyte colony stimulating factors) market size is expected to see steady growth in the next few years. It will grow to $10.98 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The anticipated growth in the forecast period can be attributed to the increasing prevalence of cancer, a rising demand for prophylaxis granulocyte colony-stimulating factor (G-CSF), an escalation in healthcare expenditure, the high potential of emerging economies, technological advances, and the widespread adoption of biosimilar drugs. Noteworthy trends expected in the forecast period include substantial investments in research and development activities to foster the creation of effective and innovative drugs, a heightened focus on merger and acquisition growth strategies to broaden the customer base and geographic markets, the establishment of strategic partnerships with major players to expand research and development activities for new drug developments, and a concerted effort toward biosimilar production for the treatment of neutropenia to enhance revenues and product offerings.

The growth of the G-CSF (granulocyte colony stimulating factor) market is significantly influenced by the increasing prevalence of cancer. Cancer, ranking as the second leading cause of death globally, accounts for approximately 1 in 6 deaths worldwide. For example, data from the American Cancer Society in January 2023 indicates that an estimated 1,958,310 new cancer cases and 609,820 cancer-related deaths are projected in the United States for the year 2023. G-CSF, a category of growth factors, plays a crucial role in generating white blood cells in the bone marrow, thereby reducing the risk of infection and sepsis. In cancer patients, G-CSF aids in accelerating recovery and decreasing mortality associated with neutropenia following cancer chemotherapy. Moreover, it has the potential to mitigate infections after specific cancer treatments. Consequently, the increasing prevalence of cancer is poised to be a driving force behind the expansion of the G-CSF market.

The anticipated rise in healthcare expenditure is expected to act as a catalyst for the future growth of the G-CSF market. Healthcare expenditure encompasses the financial outlay on various healthcare components, including medical equipment, pharmaceuticals, hospital care, physician services, and public health initiatives. The level of healthcare expenditure holds significant implications for the G-CSF market, influencing aspects such as cost-effectiveness, adoption rates, cost savings, market growth, and budgetary considerations related to G-CSF products. As evidenced by the 2021–2030 National Health Expenditure (NHE) report from the Centers for Medicare & Medicaid Services, annual national health spending is projected to witness an average increase of 5.1% between 2021 and 2030, reaching an estimated $6.8 trillion by 2030. Furthermore, Medicare expenditures are anticipated to grow at a 7.2% annual rate, and Medicaid spending is projected to increase at a 5.6% annual rate during the same period. Consequently, the upswing in healthcare expenditure emerges as a key driver for the growth of the G-CSF market.


Companies in the G-CSF (granulocyte colony stimulating factor) market are strategically emphasizing collaborations to foster innovation and expand their market share. The trend of partnerships, in-licensing, and out-licensing deals has been on the rise, with companies engaging in collaborative ventures with each other, as well as with academic and research institutions. A notable instance from 2022 involves Evive Biotech, a Singapore-based biopharmaceutical company, joining forces with the German pharmaceutical company APOGEPHA. The exclusive long-term license agreement was established for the commercialization of Efbemalenograstim alfa (F-627) in Germany and Switzerland. F-627, a novel dimeric G-CSF long-acting fusion protein without pegylation, holds promise as a significant product in the market.

Major players in the G-CSF market are actively integrating automation into their product offerings, particularly in the form of automated injection devices, to gain a competitive advantage. Automated injection devices are medical devices designed to deliver a dose of G-CSF automatically into the body at a predetermined time post-chemotherapy. A case in point is Kyowa Kirin Co. Ltd., a Japanese pharmaceutical company, which introduced G-Lasta Subcutaneous Injection 3.6 mg BodyPod in December 2022. This long-acting G-CSF preparation aims to reduce the incidence of febrile neutropenia in patients undergoing cancer chemotherapy. The automated injection device administers a G-Lasta dose approximately 27 hours after connection, eliminating the need for an additional outpatient visit the following day for G-Lasta administration.

In December 2021, when Novartis AG, a Swiss pharmaceutical company, acquired Gyroscope Therapeutics Holdings plc for $800 million. This strategic move is expected to enhance Novartis's portfolio by incorporating G-CSF drugs, bolster gene therapy research capabilities, and bring innovative ophthalmic solutions to treat and prevent blindness on a global scale. Gyroscope Therapeutics Holdings PLC, a UK-based clinical-stage biopharmaceutical company, specializes in the research and development of biosimilars for the treatment of eye-related diseases.

Major companies operating in the g-csf (granulocyte colony stimulating factors) market report are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd., BioCad, Stada Arzneimittel, Dong-A Socio Group, Dr. Reddy's Laboratories, Celltrion Inc., Emcure Pharmaceuticals, Accord Healthcare UK, Intas Pharmaceuticals, Spectrum Pharmaceuticals, Apobiologix, Apotex Inc., Eurofarma Laboratórios, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, GlaxoSmithKline PLC, AstraZeneca, Merck Sharp & Dohme Corp., Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Cipla.

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2023. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the g-csf (granulocyte colony stimulating factors) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Key types within the G-CSF market include lenograstim, filgrastim, Pegfilgrastim, and others. Lenograstim is a glycosylated recombinant therapeutic drug that closely resembles or is identical to a naturally occurring human granulocyte colony-stimulating factor (G-CSF). The various products are available in forms such as tablets, capsules, and others, and find applications in treating oncological diseases, blood disorders, growth hormone deficiencies, chronic and autoimmune disorders, among others.

The G-CSF (Granulocyte Colony Stimulating Factors) market research report is one of a series of new reports that provides G-CSF (Granulocyte Colony Stimulating Factors) market statistics, including G-CSF (Granulocyte Colony Stimulating Factors) industry global market sizes, regional shares, competitors with a G-CSF (Granulocyte Colony Stimulating Factors) market share, detailed G-CSF (Granulocyte Colony Stimulating Factors) market segments, market trends and opportunities, and any further data you may need to thrive in the G-CSF (Granulocyte Colony Stimulating Factors) industry. This G-CSF (granulocyte colony stimulating factors) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The G-CSF (granulocyte colony stimulating factors) market consists of sales of releuko, accofil, and pegylated. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.